DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+21.45%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.75B
AUM Growth
+$5.75B
(+6.1%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
4.22%
Top 10 Holdings %
Top 10 Hldgs %
51.71%
Holding
447
New
223
Increased
64
Reduced
46
Closed
77
Top Buys
| 1 |
BioNTech
BNTX
|
$52.5M |
| 2 |
Kyverna Therapeutics
KYTX
|
$36.3M |
| 3 |
Perspective Therapeutics
CATX
|
$33.5M |
| 4 |
Larimar Therapeutics
LRMR
|
$32.6M |
| 5 |
Surgery Partners
SGRY
|
$32.3M |
Top Sells
| 1 |
Viking Therapeutics
VKTX
|
$66.9M |
| 2 |
SWTX
SpringWorks Therapeutics
SWTX
|
$64M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$62.6M |
| 4 |
Baxter International
BAX
|
$57.8M |
| 5 |
Neurocrine Biosciences
NBIX
|
$28.4M |
Sector Composition
| 1 | Healthcare | 88.87% |
| 2 | Industrials | 0.71% |
| 3 | Technology | 0.31% |
| 4 | Consumer Discretionary | 0.26% |
| 5 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Verastem
VSTM
$585M
| $18.2M | 0.32% |
1,538,461
| – | – |
|
52
QuidelOrtho
QDEL
$1.87B
| $16.7M | 0.29% |
348,000
| – | – |
|
53
Guardant Health
GH
$8.11B
| $16.3M | 0.28% |
791,735
| – | – |
|
54
Fate Therapeutics
FATE
$115M
| $16.1M | 0.28% |
+2,190,408
| New | +$16.1M |
|
55
NewAmsterdam Pharma
NAMS
$2.8B
| $15.8M | 0.27% |
+667,000
| New | +$15.8M |
|
56
Lantheus
LNTH
$3.75B
| $14.9M | 0.26% |
+240,187
| New | +$14.9M |
|
57
enGene Holdings
ENGN
$249M
| $13.6M | 0.24% |
+800,000
| New | +$13.6M |
|
58
Tango Therapeutics
TNGX
$745M
| $12.2M | 0.21% |
1,540,000
| – | – |
|
59
EyePoint Pharmaceuticals
EYPT
$827M
| $12M | 0.21% |
+579,594
| New | +$12M |
|
60
Cogent Biosciences
COGT
$1.83B
| $10.3M | 0.18% |
1,534,345
+445,000
| +41% | +$2.99M |
|
|
ITOS
61
DELISTED
iTeos Therapeutics
ITOS
| $9.86M | 0.17% |
723,000
| – | – |
|
62
Replimune Group
REPL
$460M
| $6.56M | 0.11% |
802,984
-1,008,726
| -56% | -$8.24M |
|
63
Alector
ALEC
$282M
| $6.46M | 0.11% |
1,072,845
+5,035
| +0.5% | +$30.3K |
|
64
Prime Medicine
PRME
$595M
| $6.2M | 0.11% |
885,314
| – | – |
|
65
Fractyl Health
GUTS
$66.2M
| $6.17M | 0.11% |
+834,254
| New | +$6.17M |
|
66
GeneDx Holdings
WGS
$3.65B
| $5.87M | 0.1% |
643,110
| – | – |
|
67
The Oncology Institute
TOI
$302M
| $5.31M | 0.09% |
3,360,052
| – | – |
|
68
Annexon
ANNX
$225M
| $4.19M | 0.07% |
583,913
| – | – |
|
69
CalciMedica
CALC
$45M
| $4.16M | 0.07% |
+1,000,000
| New | +$4.16M |
|
|
VIGL
70
DELISTED
Vigil Neuroscience
VIGL
| $3.34M | 0.06% |
980,311
-193,212
| -16% | -$659K |
|
71
BiomX
PHGE
$14.1M
| $2.75M | 0.05% |
+6,110,098
| New | +$2.75M |
|
|
OMIC
72
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $2.56M | 0.04% |
4,984,871
| – | – |
|
|
CMAX
73
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $2.55M | 0.04% |
529,108
-15,344,105
| -97% | +$5 |
|
74
CG Oncology
CGON
$2.19B
| $2.09M | 0.04% |
+47,540
| New | +$2.09M |
|
75
DXC Technology
DXC
$2.6B
| $1.32M | 0.02% |
+62,245
| New | +$1.32M |
|